Abstract: Persistence of HBV covalently closed circular DNA (cccDNA) in hepatocyte is one of the key obstacles
in resolve of chronic hepatitis B. Currently available anti-HBV drugs have no effect on cccDNA. With the further
understanding to basic mechanism of HBV cccDNA dynamics and function, now anti-HBV studies targeting
different aspects of cccDNA dynamics were developed: specific degradation of cccDNA with APOBEC3 induced
by IFN-α and lymphotoxin-β receptor angonists, RNA silencing targeting nucleous localiztion siganl of rcDNA,
specific cleavage with CRISPR-Cas9 on cccDNA, epigenetic regulation of cccDNA and regulation of hepatocyte
metabolism related to cccDNA function. Primary results of in vivo and in vitro studies showed inhibition of
quantification and function of cccDNA, which bring hope for cure of HBV infection.